# US 2001/0025097 A1 · Somatostatins and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025097 A1
- Document ID: US20010025097A1
- Status: Published application
- Kind: A1
- Application number: 09/727,739
- Filed: 2000-12-01
- Published: 2001-09-27
- Earliest claimed: 1999-12-03
- Assignees: NDSU Research Foundation
- Inventors: Mark A. Sheridan; Jeffrey D. Kittelson; Craig A. Moore
- Web page: https://patentgrep.com/patent/US20010025097A1

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 38/31: Somatostatins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Novel somatostatin polypeptides derived from Oncorhynchus mykiss, polynucleotides encoding novel somatostatin polypeptides, and methods for identifying bioactive modified somatostatin polypeptides.

## Claims

### Claim 1

A somatostatin polypeptide or bioactive analog or subunit thereof, the somatostatin polypeptide comprising at least one amino acid sequence comprising at least one of a portion of Oncorhynchus mykiss preprosomatostatin I (PPSS-I; SEQ ID NO:3) and a portion of Oncorhynchus mykiss preprosomatostatin II″ (PPSS-II″; SEQ ID NO:9).

### Claim 2 (depends on 1)

The somatostatin polypeptide or bioactive analog or subunit thereof of claim 1, wherein the somatostatin polypeptide comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 15, 17, 18, and 19.

### Claim 3

A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs:3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 15, 17, 18, and 19.

### Claim 4 (depends on 1)

A polynucleotide comprising at least one nucleotide sequence that encodes at least one somatostatin polypeptide or bioactive analog or subunit thereof of claim 1.

### Claim 5 (depends on 4)

The polynucleotide of claim 4 comprising SEQ ID NO:8 or SEQ ID NO:20.

### Claim 6 (depends on 4)

A polynucleotide that is substantially complementary to the polynucleotide of claim 4.

### Claim 7

A method for identifying a modified somatostatin polypeptide comprising:
(a) providing an amino acid sequence of a somatostatin polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs:3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 15, 17, 18, and 19;
(b) aligning the amino acid sequence of the somatostatin polypeptide of step(a) with the amino acid sequence of a reference somatostatin polypeptide;
(c) identifying at least one site or region of differing amino acid sequence; and
(d) modifying the amino acid sequence of the somatostatin polypeptide of step (a) or the reference somatostatin polypeptide at the identified site or region to incorporate at least one amino acid substitution, insertion, or deletion from the analogous site or region in the other somatostatin polypeptide to yield the amino acid sequence of a modified somatostatin polypeptide.

### Claim 8 (depends on 7)

The method of claim 7 further comprising (e) synthesizing the modified somatostatin polypeptide and (f) assaying the modified somatostatin polypeptide for biological activity.

### Claim 9 (depends on 8)

The method of claim 8 wherein step (e) comprises assaying the binding of the modified somatostatin polypeptide to a human somatostatin receptor.

### Claim 10 (depends on 7)

The method of claim 7 wherein the reference somatostatin polypeptide is a mammalian somatostatin polypeptide.

### Claim 11 (depends on 7)

The method of claim 7 wherein the modified somatostatin polypeptide is a somatostatin agonist or antagonist.

### Claim 12

A fusion polypeptide comprising an N-terminal somatostatin region comprising at least one first amino acid sequence comprising at least one of a portion of O. mykiss preprosomatostatin I (PPSS-I; SEQ ID NO:3) and a portion of O. mykiss preprosomatostatin II″ (PPSS-II″; SEQ ID NO:9) covalently linked to a C-terminal region comprising a second amino acid sequence.

### Claim 13 (depends on 12)

The fusion polypeptide of claim 12 wherein the second amino acid sequence encodes a bioactive moiety.

### Claim 14 (depends on 12)

The fusion polypeptide of claim 12 wherein the first amino acid sequence comprises at least one amino acid sequence selected from the group consisting of NOs:3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 15, 17, 18, and 19.

### Claim 15 (depends on 13)

The fusion polypeptide of claim 13 wherein the first amino acid sequence comprises SEQ ID NO:6 or SEQ ID NO:18.
